MULTITUDE THERAPEUTICS
Multitude Therapeutics develops drugs for the treatment of tumors. It focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts, and immuno-oncology antibodies for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart. The company was founded in 2018 and is based in Xuhui, Shanghai, China.
MULTITUDE THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Medical Pharmaceutical Therapeutics
Founded:
2018-01-01
Address:
Xuhui, Shanghai, China
Country:
China
Website Url:
http://www.multitudetherapeutics.com
Total Employee:
11+
Status:
Active
Total Funding:
0
Investors List
Northern Light Venture Capital
Northern Light Venture Capital investment in Venture Round - Multitude Therapeutics
Official Site Inspections
http://www.multitudetherapeutics.com
- Host name: 59.110.25.28
- IP address: 59.110.25.28
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Multitude Therapeutics"
Multitude Therapeutics - Crunchbase Company Profile …
Multitude Therapeutics develops drugs for the treatment of tumors. It focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts, and immuno …See details»
Mulitude Therapeutics
Multitude Therapeutics is a clinical stage biopharmaceutical company established in 2019 to leverage its unparalleled target and antibody discovery arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) , combined with a …See details»
Multitude Therapeutics - LinkedIn
Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel ...See details»
Multitude Therapeutics Company Profile | Management and
Find contact information for Multitude Therapeutics. Learn about their Research & Development, Business Services market share, competitors, and Multitude Therapeutics's email format.See details»
Multitude Therapeutics - VentureRadar
Develops novel cancer therapeutics using proprietary antibody discovery arrays and ADC platform to treat malignancies with high unmet medical needs, including first-in-class and best-in-class …See details»
关于普众-Ms - Multitude Therapeutics
普众发现是一家专注于ADC药物开发的临床阶段公司，公司创始人具有连续成功的创业经验。普众发现能够开发出行业领先的ADC产品，其竞争优势在于具有两个技术平台：MabArray （Sci …See details»
Multitude Therapeutics, Inc. (China) - Drug pipelines, Patents ...
Explore Multitude Therapeutics, Inc. (China) with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, and 1 literature, Disease Domain:Neoplasms, Endocrinology and …See details»
Multitude Therapeutics – Life Science Directory
Multitude Therapeutics Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. …See details»
Multitude Therapeutics - Products, Competitors, Financials, …
Multitude Therapeutics is a clinical stage biopharmaceutical company that operates in the healthcare and pharmaceutical industry. Use the CB Insights Platform to explore Multitude …See details»
Multitude Therapeutics: Contact Details and Business Profile
Multitude Therapeutics is a Biotechnology Research, Drug Discovery, and Pharmaceuticals company located in US with 7 employees. Find top employees, contact details and business …See details»
Multitude Therapeutics 2025 Company Profile: Valuation, Funding ...
Information on valuation, funding, cap tables, investors, and executives for Multitude Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Multitude Therapeutics | Insights
The case for the US Food and Drug Administration to make Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s HER3-targeting antibody-drug conjugate (ADC) patritumab deruxtecan the first anti …See details»
Multitude Therapeutics | VentureRadar
Multitude Therapeutics is established in 2019 to leverage its unparalleled target and antibody discovery arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) , …See details»
Overview, News & Similar companies - ZoomInfo.com
Jan 30, 2024 View Multitude Therapeutics (www.multitudetherapeutics.info) location in California, United States , revenue, industry and description. Find related and similar …See details»
Technology - Multitudetx
Cancer Target Atlas Enabled by MabArrayTM： Industrialized hybridoma development capability for efficient generation of large-scale library against cancer/immune proteomes Current library …See details»
Multitude Therapeutics | BIO-Europe - Informa Connect
Multitude Therapeutics is a clinical-stage biotech developing FIC/BIC ADCs by its unparalleled target and antibody discovery MabArray technology, a high-throughput screening of live cells …See details»
Multitude Therapeutics, Inc. (China) (普众发现医药科技（上海）有 …
了解Multitude Therapeutics, Inc. (China) (普众发现医药科技（上海）有限公司)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验和1篇文献，疾病领域:肿瘤，内分泌与代谢疾 …See details»
Adcendo ApS and Multitude Therapeutics Inc. Announce Global …
Aug 20, 2024 COPENHAGEN, Denmark and SHANGHAI, Aug. 20, 2024 /PRNewswire/ -- Adcendo ApS ("Adcendo") and Multitude Therapeutics Inc. ("Multitude") jointly announced …See details»
Adcendo ApS and Multitude Therapeutics Inc. Announce Global …
August 20th, 2024, Copenhagen, Denmark and Shanghai, China — Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a …See details»
Adcendo ApS and Multitude Therapeutics Inc. Announce Global …
According to the financial terms of the agreement, Multitude would receive upfront and milestone payments upon achieving development, regulatory, and commercial milestones totally over $1 …See details»